C07C 211/29
The carbon skeleton being further substituted by halogen atoms or by nitro
Official title: the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
C07C211/29 (The carbon skeleton being further substituted by halogen atoms or by nitro) appears on 266 US grants and 236 published applications in this corpus.
Search patents in C07C- Granted patents
- 266
- Published applications
- 236
- Assignees
- 174
- Inventors
- 818
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 3 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 3 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 3 | 0 |
| 1991 | 7 | 0 |
| 1992 | 6 | 0 |
| 1993 | 4 | 0 |
| 1994 | 5 | 0 |
| 1995 | 9 | 0 |
| 1996 | 8 | 0 |
| 1997 | 11 | 0 |
| 1998 | 6 | 0 |
| 1999 | 6 | 0 |
| 2000 | 10 | 0 |
| 2001 | 9 | 0 |
| 2002 | 7 | 7 |
| 2003 | 5 | 7 |
| 2004 | 9 | 14 |
| 2005 | 7 | 6 |
| 2006 | 6 | 10 |
| 2007 | 5 | 15 |
| 2008 | 11 | 9 |
| 2009 | 4 | 9 |
| 2010 | 3 | 13 |
| 2011 | 5 | 6 |
| 2012 | 4 | 11 |
| 2013 | 5 | 12 |
| 2014 | 6 | 16 |
| 2015 | 12 | 9 |
| 2016 | 13 | 18 |
| 2017 | 18 | 21 |
| 2018 | 3 | 6 |
| 2019 | 9 | 14 |
| 2020 | 15 | 15 |
| 2021 | 7 | 4 |
| 2022 | 5 | 2 |
| 2023 | 5 | 4 |
| 2024 | 1 | 2 |
| 2025 | 2 | 2 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Heterocyclyl pyrimidines and triazines as novel fungicides3 Mar 2026US 12,565,489 B2Bayer Aktiengesellschaft
- Capsazepine analogs for the treatment of cancer and other proliferative diseases15 Jul 2025US 12,358,909 B2Board of Regents, The University of Texas System
- Substituted piperazines as disrupters of AB42 oligomer formation27 May 2025US 12,312,296 B2Acelot, Inc.
- Sphingosine kinase inhibitors23 Jan 2024US RE49,811 E1Apogee Biotechnology Corporation
- Substituted amines as disrupters of ABETA42 oligomer formation28 Nov 2023US 11,827,582 B2Acelot, Inc.
- Catalyst for sp3-carbon-hydrogen-bond primary amination reaction, and method for preparing primary amine compound13 Aug 2026US 2026/0234096 A1West China Second University Hospital, Sichuan University
- Small molecule drugs and related methods for treatment of diseases related to ab42 oligomer formation25 Jun 2026US 2026/0176230 A1Acelot, Inc.
- Compounds and methods for treating cancer18 Jun 2026US 2026/0166051 A1The Regents of the University of California
- Pi3k-alpha inhibitors and methods of use thereof5 Feb 2026US 2026/0035335 A1Relay Therapeutics, Inc.
- Effective means to modulate nmda receptor-mediated toxicity6 Nov 2025US 2025/0339402 A1Fundamental Pharma GmbH
Most cited
By later US patents
- Bioactive and/or targeted dendrimer conjugates232US 5,714,166 ADendritech, Inc. · 1998
- Dense star polymer conjugates191US 5,527,524 AThe Dow Chemical Company · 1996
- Starburst conjugates168US 5,338,532 AThe Dow Chemical Company · 1994
- Sigma receptor ligands and the use thereof150US 6,057,371 AVirginia Commonwealth University · 2000
- Calcium receptor-active molecules72US 6,031,003 ANPS Pharmaceuticals, Inc. · 2000